Posted inClinical Updates Hematology-Oncology Oncology
Derazantinib in FGFR2-Altered Intrahepatic Cholangiocarcinoma: Promising Phase 2 Efficacy with Manageable Toxicity
A pivotal Phase 2 study demonstrates that derazantinib yields meaningful responses and progression-free survival in FGFR2-aberrant advanced intrahepatic cholangiocarcinoma, with an acceptable safety profile, supporting its role as a targeted therapeutic option post-chemotherapy.